Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +1.92% | -13.47% | -9.79% |
11/06 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
11/06 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.79% | 44Cr | - | ||
+6.37% | 22TCr | B | ||
+10.21% | 19TCr | B- | ||
+28.22% | 15TCr | B- | ||
+34.42% | 11TCr | A- | ||
+0.80% | 6.32TCr | A- | ||
+19.21% | 5.48TCr | B+ | ||
+0.13% | 4.85TCr | B+ | ||
-4.16% | 3.89TCr | A | ||
+2.39% | 3.61TCr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MXCT Stock
- MXCT Stock
- Ratings MaxCyte, Inc.